1402041-76-2

Upstream product

• 59-88-1 phenylhydrazine hydrochloride 
• 70598-12-8 [3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid 
• 70598-19-5 [3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl]acetonitrile 
• 372107-20-5 4-(chloromethyl)-3-(4-bromophenyl)-1-phenyl-1H-pyrazole 
• 36640-55-8 (3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl)methanol 
• 36640-41-2 3-(4-bromophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde 
• 99-90-1 para-bromoacetophenone 
• 98-64-6 4-Chlorobenzenesulfonamide 
• 1402041-73-9 (3-{4-[(4-chlorophenyl)ethynyl]phenyl}-1-phenyl-1H-pyrazol-4-yl)acetic acid 
• 1402041-82-0 ethyl 2-(3-(4-(2-(4-chlorophenyl)ethynyl)phenyl)-1-phenyl-1H-pyrazol-4-yl)acetate 
• 1402041-80-8 ethyl [3-(4-bromophenyl)-1-phenyl-1H-pyrazol-4-yl]acetate 

Relevant academic research and scientific papers

Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX

mPGES-1 is a promising target for development of new anti-inflammatory drugs. We aimed to create mPGES-1 inhibitors by modifying the structure of NSAIDs by replacing the carboxylic acid functionality by sulfonamide moieties. Compounds were also tested for